Pages

Thursday, November 6, 2014

Tim Gallagher shared an article with you from Pocket

 
 
 
Tim Gallagher shared with you:
 
 
  Very exciting and very close to fruition. (Except Theranos.)  
 
 
 
  10 Ideas That Are About To Change Medicine Forever  
 
  businessinsider.com  
     
 
 
 
Don't have time to view this now?
Sign up for Pocket and view this page later.
     
  Get Pocket  
     
 
 

Wednesday, March 12, 2014

Tim Gallagher shared an article from Pocket: Pharmaceutical Scouts Seek New Star Drugs for Cancer, Diabetes

 
 
 
Tim Gallagher shared with you:
 
 
  Here's a view inside drug partnering, with the main point being that Big Pharma is much more open to collaboration. That isn't news to most, but still good personal insights in the article. I'm surprised, though at one of the stats in the article: 33% of all Big Pharma leads are in-licensed. Put another way, 2/3rds of all Big Pharma programs are still internally sourced. That doesn't seem right - internal discovery in Big Pharma seems to me to have shrunken to a minority activity - maybe 25% of all big Pharma R&D. What's your impression?  
 
 
 
  Pharmaceutical Scouts Seek New Star Drugs for Cancer, Diabetes  
 
  online.wsj.com  
     
 
 
 
Don't have time to view this now?
Sign up for Pocket and view this page later.
     
  Get Pocket  
     
 
 

Tuesday, February 25, 2014

Molecular Diagnostics Are in a Rut. The Industry Needs the FDA

 
 
 
Tim Gallagher shared with you:
 
 
  A good look at the muddled state of molecular diagnostics.  
 
 
 
  Molecular Diagnostics Are in a Rut. The Industry Needs the FDA  
 
  xconomy.com  
     
 
 
 
Don't have time to view this now?
Sign up for Pocket and view this page later.
     
  Get Pocket  
     
 
 

Tuesday, June 4, 2013

The Logic Of Biologics - Is Regeneron The Next Roche?



Tim Gallagher shared with you:
Interesting stats from this article showing the value of Biologics >small molecules "For preclinical compounds, it takes an average of 44 small-molecule candidates to achieve one final approval versus nine biologic drug candidates In Phase II development, it takes an average of 11 small-molecule candidates to achieve one final approval versus four biologic drug candidates Only 19 percent of small-molecule compounds will advance from Phase II to Phase III studies, versus 44 percent for biologics Only 60 percent of small-molecule compounds will successfully complete Phase III studies versus 79 percent for biologics"
 
The Logic Of Biologics - Is Regeneron The Next Roche?
forbes.com
For preclinical compounds, it takes an average of 44 small-molecule candidates to achieve one final approval versus nine biologic drug candidates In Phase II development, it takes an average of 11 small-molecule candidates to achieve one final approval versus four biologic drug candidates Only 19 percent of small-molecule compounds will advance from Phase II to Phase III studies, versus 44 percent for biologics Only 60 percent of small-molecule compounds will successfully complete Phase III studies versus 79 percent for biologics